Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AGN-190168 Formulation 1, AGN-190168 Formulation 2
AGN-190168 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| AGN-190168 Formulation 1 | EXPERIMENTAL | AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days. |
| AGN-190168 Formulation 2 | EXPERIMENTAL | AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days. |
| TAZORAC® Gel 0.1% | ACTIVE_COMPARATOR | TAZORAC® Gel 0.1% (tazarotene gel 0.1%) applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days. |
| TAZORAC® Cream 0.1% | ACTIVE_COMPARATOR | TAZORAC® Cream 0.1% (tazarotene cream 0.1%) applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days. |
| Name | Type | Description |
|---|---|---|
| AGN-190168 Formulation 1 | DRUG | AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days. |
| AGN-190168 Formulation 2 | DRUG | AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days. |
| tazarotene gel 0.1% | DRUG | Tazarotene gel 0.1% applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days. |
| tazarotene cream 0.1% | DRUG | Tazarotene cream 0.1% cream applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days. |
Inclusion Criteria: * Diagnosis of acne vulgaris on the face * No tobacco use for the past 30 days, and willing to refrain from nicotine use during the study * Willing to avoid excessive or prolonged exposure of the treated skin to ultraviolet light (eg, sunlight, tanning beds) and extremes in weat...
AGN-190168 is an investigational small molecule being developed by AbbVie Inc. for the treatment of acne vulgaris. It has been studied in a Phase 1 clinical trial evaluating safety, tolerability, and pharmacokinetics in subjects with acne vulgaris. It is not approved and remains in clinical development.
AGN-190168 is being developed for the treatment of acne vulgaris, a common dermatological condition. Its clinical evaluation has focused on subjects with acne vulgaris, including adolescents as young as 12 years of age. The drug is investigational and has not been approved for any use.
AGN-190168 is developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie is the sponsor of the clinical program evaluating the compound in acne vulgaris.
AGN-190168 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The compound is investigational and has not been approved by the FDA for acne vulgaris or any other indication.
AGN-190168 has been evaluated in the Phase 1 trial NCT02218034, titled Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris. The trial enrolled 78 participants in the United States, was randomized and active-controlled, and has been completed.
Yes. AGN-190168 is also known as AGN-190168 Formulation 1 and AGN-190168 Formulation 2. These names refer to the same investigational compound developed by AbbVie for acne vulgaris, so searches using any of these names point to the same drug asset.